Amiodarone Oral

Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100: 2025-2034. Nattel S, Talajic M, Fermini B, Roy D. Amiodarone: Pharmacology, clinical actions, and relationships between them. J Cardiovasc Electrophysiol 1992;3:266-280. Bosch RF, Li G-R, Gaspo R, Nattel S. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999;289:156-165. Kodama I, Kamiya K, Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agents. Am J Cardiol 1999;84:20R-28R. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29. Roden DM. Mechanisms underlying variability in response to drug therapy: Implications for amiodarone use. Am J Cardiol 1999;84:29R-36R. Libersa CC, Brique SA, Motte KB, Caron JF, Guedon-Moreau LM, Humbert L, Vincent A, Devos P, Lhermitte MA. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000;49:373-378. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions. Br J Clin Pharmacol 2000;49:244-253. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg M, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B, for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913-920. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation: an evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-371. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-1424. Peuhkurinen K, Niemela M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol 2000;85:462-465. Kochiadakis GE, Igoumenidis NE, Mavrakis HE, Kalebubas MD, Marketou ME, Zacharis EZ, Vardas PE. Amiodarone for the conversion of recent onset atrial fibrillation: Which route of administration is superior, intravenous or oral? Pace 2000;23(Part II):648. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:66-73. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, Pagani FD, Bitar C, Meissner MD, Morady F. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997;337:1785-1791. Katariya K, DeMarchena E, Bolooki H. Oral amiodarone reduces incidence of postoperative atrial fibrillation. Ann Thorac Surg 1999;68:1599-1603. Redle JD, Khurana S, Marzan R, McCullough PA, Stewart JR, Westveer DC, O'Neill WW, Bassett JS, Tepe NA, Frumin HI. Prophylactic oral amiodarone compared with placebo for prevention of atrial fibrillation after coronary artery bypass surgery. Am Heart J 1999;138:144-150. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583. Kuck KH. CASH press release. American College of Cardiology, March 1998. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O'Brien B. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1302. Connolly SJ, Krahn A, Klein G. Long term management of the survivor of ventricular fibrillation or sustained ventricular tachycardia. Canadian Cardiovascular Society Consensus Conference. The prevention of sudden cardiac death from ventricular arrhythmia. Can J Cardiol. 2000;16(SupplC):20C-22C. Marchlinski FE, Zado ES, Deely MP, Saligan J, Ashar M, Nayak H. Concomitant device and drug therapy: Current trends, potential benefits, and adverse interactions. Am J Cardiol 1999;84:69R-75R. Haberman RJ, Velhi EP, Mower MM. The effect of amiodarone on defibrillation threshold. J Electro Physiol 1998;2:415-423. Cairns JA, Connolly SJ, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, for the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-674. Elizari MV, Martinez JM, Belziti C, Ciruzzi M, Perez de la Hoz R, Sinisi A, Carbajales J, Scapin O, Garguichevich J, Girotti L, Cagide A, on behalf of the GEMICA Study Investigators. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction. Eur Heart J 2000;21:198-205. Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, Gent M, Janse MJ, Dorian P, Frangin G, for the EMIAT and CAMIAT Investigators. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (The European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. Circulation 1999;99:2268-2275. Kaye DM, Dart AM, Jennings GL, Esler MD. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J Am Coll Cardiol 1999;33:1553-1559. Macdonald PS, Keogh AM, Aboyoun C, Lund M, Amor R, McCaffrey D. Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure. Heart 1999;82:589-593. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol 1999;84:90R-93R. Sheinman MM. Amiodarone after acute myocardial infarction. Eur Heart J 2000;21:177-178. Naccarelli GV, Wolbrette DL, Patel HM, Luck JC. Amiodarone: Clinical trials. Curr Opin Cardiol 2000;15:64-72. Singh BN. Amiodarone: The expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608-618. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999;127:610-612. Sreih AG, Scheonfeld MH, Marieb MA. Optic neuropathy following amiodarone therapy. Pacing Clin Electrophysiol 1999;22:1108-1110. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42:360-366. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low-dose amiodarone:A meta-analysis. J Am Coll Cardiol 1997;30:791-798. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary manifestations. Am J Cardiol 1999;84:37R-45R. Jessurum GA, Boersma WG, Crijns HJ. Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Drug Safety 1998;18:339-344. Loh KC. Amiodarone-induced thyroid disorders: A clinical review. Postgrad Med J 2000;76:133-140. Vandergheynst F, Lienart F, Ducobu J. Amiodarone and thyroid disorders-prospective study and review of the literature. Rev Med Brux 1999;20:411-417. Sato K, Miyakawa M, Eto M, Inaba T, Matsuda N, Shiga T, Ohnishi S, Kasanuki H. Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocr J 1999;46:443-451. Claxton S, Singh SN, Donovan S, Greenaway TM, Hoffman L, Loughhead M, Burgess JR. Refractory amiodarone-associated thyrotoxicosis: An indication for thyroidectomy. Aust N Z J Surg 2000;70:174-178. Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: Risk factors in adults with congenital heart disease. Circulation 1999;100:149-154. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Takeshita A. Amiodarone protects cardiac myocytes against oxidative injury by its free radical scavenging action. Circulation 1999;100:690-692. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: Comparison with amiodarone. Circulation 1999;100:2276-2281.